Gilead Sciences

News

Gilead finds survival boost with remdesivir with unorthodox ...

Gilead says an analysis of clinical trial and retrospective real-world data suggest remdesivir can improve survival in severe COVID-19 infections, but adds controlled studies a

News

Gilead starts trials of inhaled remdesivir for earlier-stage...

The first healthy volunteers have started to receive doses of Gilead’s inhaled formulation of remdesivir, which it hopes could become an option for earlier-stage COVID-19 outsi

News

Gilead finally breaks its silence on remdesivir’s price

After weeks of speculation, Gilead Sciences has revealed its pricing plans for coronavirus drug remdesivir – and the rationale behind its decision.

News

US advisors add steroids to COVID-19 drug recommendations

The Infectious Diseases Society of America (IDSA) says generic steroids should be used to treat patients hospitalised with COVID-19.

News

Pills spilling out of a prescription bottle on 100 dollar paper currency

After Celgene deal, BMS shoots up pharma market cap rankings

Bristol-Myers Squibb $74 billion takeover of Celgene saw it shoot up the list of top 20 pharma companies by market cap into the top 10, according to a new analysis by GlobalDat

News

Patient on hospital bed with saline solution tube

Gilead will test remdesivir in children with COVID-19

Gilead Sciences has said it will start trials soon of its antiviral drug remdesivir in children – from newborns to adolescents – who have moderate-to-severe COVID-19.

Gilead finds survival boost with remdesivir with unorthodox ...

Gilead starts trials of inhaled remdesivir for earlier-stage...

Gilead finally breaks its silence on remdesivir’s price

US advisors add steroids to COVID-19 drug recommendations

After Celgene deal, BMS shoots up pharma market cap rankings

Gilead will test remdesivir in children with COVID-19

Iambic prices its IPO, seeking to raise up to $160m

Discover a new era of healthcare panel engagement: Grounded ...

Gilead Sciences

Editor's Picks